166 related articles for article (PubMed ID: 38474324)
1. Advanced Therapy Medicinal Products as Potential Therapeutic Strategy against COVID-19 and Immune-Related Disorders.
Mallis P; Michalopoulos E; Stavropoulos-Giokas C
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474324
[TBL] [Abstract][Full Text] [Related]
2. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
3. Emerging technologies for quality control of cell-based, advanced therapy medicinal products.
Zia S; Pizzuti V; Paris F; Alviano F; Bonsi L; Zattoni A; Reschiglian P; Roda B; Marassi V
J Pharm Biomed Anal; 2024 Aug; 246():116182. PubMed ID: 38772202
[TBL] [Abstract][Full Text] [Related]
4. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
[TBL] [Abstract][Full Text] [Related]
5. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
6. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand.
Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P
Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851
[TBL] [Abstract][Full Text] [Related]
7. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time.
Piemonti L; Scholz H; de Jongh D; Kerr-Conte J; van Apeldoorn A; Shaw JAM; Engelse MA; Bunnik E; Mühlemann M; Pal-Kutas K; Scott WE; Magalon J; Kugelmeier P; Berishvili E
Transpl Int; 2023; 36():11633. PubMed ID: 37822447
[TBL] [Abstract][Full Text] [Related]
8. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
9. State-of-the-art knowledge on the regulation of advanced therapy medicinal products.
Kidpun P; Ruanglertboon W; Chalongsuk R
Per Med; 2022 May; 19(3):251-261. PubMed ID: 35293224
[TBL] [Abstract][Full Text] [Related]
10. A pipeline analysis of advanced therapy medicinal products.
Wilkins GC; Lanyi K; Inskip A; Ogunbayo OJ; Brhlikova P; Craig D
Drug Discov Today; 2023 May; 28(5):103549. PubMed ID: 36963609
[TBL] [Abstract][Full Text] [Related]
11. [Classification of cell-based medicinal products and legal implications: An overview and an update].
Scherer J; Flory E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
[TBL] [Abstract][Full Text] [Related]
12. Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs).
Spoors J; Miners A; Cairns J; Palnoch D; Summerfield A; McEntee J; Vithlani S
BioDrugs; 2021 Jan; 35(1):1-5. PubMed ID: 33226582
[TBL] [Abstract][Full Text] [Related]
13. Advanced therapy medicinal products: Regulatory framework, hospital and pharmaceutical circuits in Europe and France.
Mebarki M; Madelaine I; Larghero J; de Jorna R
Therapie; 2022; 77(2):185-190. PubMed ID: 34895758
[TBL] [Abstract][Full Text] [Related]
14. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
15. Regulation of advanced therapy medicinal products in Europe and the role of academia.
Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
[TBL] [Abstract][Full Text] [Related]
16. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.
Jönsson B; Hampson G; Michaels J; Towse A; von der Schulenburg JG; Wong O
Eur J Health Econ; 2019 Apr; 20(3):427-438. PubMed ID: 30229376
[TBL] [Abstract][Full Text] [Related]
17. Horses for courses: an approach to the qualification of clinical trial sites and investigators in ATMPs.
Hildebrandt M
Drug Discov Today; 2020 Feb; 25(2):265-268. PubMed ID: 31628993
[TBL] [Abstract][Full Text] [Related]
18. European regulatory tools for advanced therapy medicinal products.
Flory E; Reinhardt J
Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890
[TBL] [Abstract][Full Text] [Related]
19. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
Beattie S;
Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
[TBL] [Abstract][Full Text] [Related]
20. The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.
Lowdell MW; Thomas A
Br J Haematol; 2017 Jan; 176(1):9-15. PubMed ID: 27748517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]